Shanetta D Ore

Array ( [id] => 16839543 [patent_doc_number] => 20210147555 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-20 [patent_title] => ANTIBODY FORMULATION [patent_app_type] => utility [patent_app_number] => 17/045380 [patent_app_country] => US [patent_app_date] => 2019-04-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045380 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15178279 [patent_doc_number] => 20190359731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-28 [patent_title] => USE OF HUMAN CELLS OF MYELOID LEUKAEMIA ORIGIN FOR EXPRESSION OF ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/376174 [patent_app_country] => US [patent_app_date] => 2019-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16376174 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14652773 [patent_doc_number] => 20190233515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-01 [patent_title] => Methods for Manipulating Phagocytosis Mediated by CD47 [patent_app_type] => utility [patent_app_number] => 16/361567 [patent_app_country] => US [patent_app_date] => 2019-03-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32116 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16361567 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18368153 [patent_doc_number] => 11648301 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-05-16 [patent_title] => Tumor vaccination in combination with hematopoietic cell transplantation for cancer therapy [patent_app_type] => utility [patent_app_number] => 16/360678 [patent_app_country] => US [patent_app_date] => 2019-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 36 [patent_no_of_words] => 31173 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 140 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16360678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15496331 [patent_doc_number] => 20200048354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-13 [patent_title] => HUMANIZED ANTI-BETA7 ANTAGONISTS AND USES THEREFOR [patent_app_type] => utility [patent_app_number] => 16/358874 [patent_app_country] => US [patent_app_date] => 2019-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45297 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16358874 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14531779 [patent_doc_number] => 20190201510 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-07-04 [patent_title] => PASSIVE VACCINE FOR ELIMINATION OF SENESCENT CELLS [patent_app_type] => utility [patent_app_number] => 16/352465 [patent_app_country] => US [patent_app_date] => 2019-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56709 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16352465 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17005453 [patent_doc_number] => 20210236614 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-08-05 [patent_title] => VACCINE COMPOSITION AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/966442 [patent_app_country] => US [patent_app_date] => 2019-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16966442 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14377631 [patent_doc_number] => 20190162728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-30 [patent_title] => METHODS AND MATERIALS FOR TREATING RENAL CELL CARCINOMA [patent_app_type] => utility [patent_app_number] => 16/264182 [patent_app_country] => US [patent_app_date] => 2019-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16264182 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16806131 [patent_doc_number] => 20210128684 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-05-06 [patent_title] => ANTI-TUMOR THERAPEUTIC AGENTS BASED ON B7H RECEPTOR LIGANDS [patent_app_type] => utility [patent_app_number] => 16/963185 [patent_app_country] => US [patent_app_date] => 2019-01-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10012 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16963185 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435756 [patent_doc_number] => 20200353081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => A COMBINATION OF PLASMA IMMUNOGLOBULIN AND ANTIGEN-SPECIFIC IMMUNOGLOBULIN FOR THE MODIFICATION OF THE IMMUNE SYSTEM AND THE TREATMENT OR PREVENTION OF ALLERGIC DISEASES [patent_app_type] => utility [patent_app_number] => 16/958609 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3547 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16958609 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16450939 [patent_doc_number] => 20200360365 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => SUBSTITUTED HALO-QUINOLINE DERIVATES FOR USE IN THE TREATMENT OF LYMPHOMAS AND LEUKEMIA [patent_app_type] => utility [patent_app_number] => 16/959950 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15145 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959950 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657440 [patent_doc_number] => 20210054076 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => CYTOTOXICITY-INDUCING THERAPEUTIC AGENT [patent_app_type] => utility [patent_app_number] => 16/959288 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959288 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16540988 [patent_doc_number] => 20200407401 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-31 [patent_title] => COMPOSITIONS AND METHODS FOR INHIBITION OF ALPHAVIRUS INFECTION [patent_app_type] => utility [patent_app_number] => 16/959867 [patent_app_country] => US [patent_app_date] => 2019-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16711920 [patent_doc_number] => 20210079067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-18 [patent_title] => NEUTRALIZING ANTIBODIES TO EBOLA VIRUS GLYCOPROTEIN AND THEIR USE [patent_app_type] => utility [patent_app_number] => 16/959644 [patent_app_country] => US [patent_app_date] => 2018-12-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24892 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -35 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16959644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18910366 [patent_doc_number] => 11873336 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-16 [patent_title] => Heavy chain antibodies binding to CD22 [patent_app_type] => utility [patent_app_number] => 16/956502 [patent_app_country] => US [patent_app_date] => 2018-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 9 [patent_no_of_words] => 12522 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16956502 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883827 [patent_doc_number] => 20210170022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => COMBINATION DRUG INCLUDING TLR7 AGONIST [patent_app_type] => utility [patent_app_number] => 16/772846 [patent_app_country] => US [patent_app_date] => 2018-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16772846 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14185359 [patent_doc_number] => 20190112384 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => COMPOSITIONS AND METHODS FOR THE DETECTION DIAGNOSIS AND THERAPY OF HEMATOLOGICAL MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 16/222746 [patent_app_country] => US [patent_app_date] => 2018-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 72166 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16222746 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14216877 [patent_doc_number] => 20190120823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-25 [patent_title] => METHODS OF TREATING A NEUROENDOCRINE TUMOR [patent_app_type] => utility [patent_app_number] => 16/194160 [patent_app_country] => US [patent_app_date] => 2018-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9372 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -70 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16194160 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016569 [patent_doc_number] => 20190070278 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => CRYOPRESERVATION OF APOPTOTIC CANCER CELLS FOR USE IN IMMUNOTHERAPY AGAINST CANCER [patent_app_type] => utility [patent_app_number] => 16/179159 [patent_app_country] => US [patent_app_date] => 2018-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19157 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16179159 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16899052 [patent_doc_number] => 20210177968 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-17 [patent_title] => DERMAL APPLICATOR FOR USE IN CANCER PHOTOIMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 16/759035 [patent_app_country] => US [patent_app_date] => 2018-10-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16560 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759035 [rel_patent_id] =>[rel_patent_doc_number] =>)